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Children and 
Multidrug-Resistant 
Tuberculosis in 
Mumbai (Bombay), 
India
To the Editor: India has the high-
est number of tuberculosis (TB) cases
in the world. Each year in India, over
2 million new cases of TB are diag-
nosed, and approximately 500,000
persons die of the disease (1). During
the last decade, multidrug-resistant TB
has burgeoned in India, resulting in an
extremely large number of multidrug-
resistant TB cases, second only to the
number of cases noted in Latvia (2).
Since 1993, in response to this epi-
demic, the government of India has
implemented the Revised National
Tuberculosis Control Program, which
is based on directly observed treat-
ment (short course) principles (1).
Mumbai (formerly Bombay),
India, is a densely populated metropo-
lis with a population of approximately
12 million, 4.8 million (40%) of
whom reside in overcrowded slums.
Since 1990, a resurgence of TB has
occurred, characterized by a 70% to
140% increase in the rate of TB-
related deaths among adults aged 25–
44 years (3). A vital factor contribut-
ing to this phenomenon is HIV infec-
tion. A recent review of autopsy
reports from Mumbai showed that 85
(59%) of 143 adult patients with AIDS
were diagnosed with pulmonary TB
(4), indicating that the disease is the
most common opportunistic infection
for persons with AIDS. Commensu-
rate with the increase in TB cases is a
surge in the prevalence of multidrug-
resistant TB in adult patients. Two ref-
erence mycobacterial laboratories in
private hospitals in Mumbai have
reported a high prevalence of multi-
drug-resistant TB strains; 56 (11%) of
521 cases in 1991–1995, and 58 (58%)
of 100 cases in 1994–1995 (5,6).
The crisis of multidrug-resistant
TB in adults in Mumbai has been well
documented (7). However, little atten-
tion has been directed at children also
affected by the resurgent TB epi-
demic. We think that TB is developing
in more children in Mumbai today
than a decade earlier. Moreover, close
proximity to adult patients with multi-
drug-resistant TB makes children
prone to developing primary multi-
drug-resistant TB, a vulnerability doc-
umented in a South African study (8).
Similarly, disseminated TB is occur-
ring in large numbers of children liv-
ing in overcrowded slums in Mumbai
with a consequent high death rate (9);
we attribute many of these deaths in
children to primary multidrug-resis-
tant TB. However, this conclusion is
difficult to document, as most affected
children are sputum-negative for acid-
fast bacilli. Contact tracing to detect
the adult source of infection is rou-
tinely undertaken; often we can trace
the source of infection. Because the
facilities for culture and susceptibility
testing are not available at affordable
rates, proving that the adult contact
has multidrug-resistant TB is not fea-
sible in most cases.
The AIDS epidemic in adults in
Mumbai has adversely affected the
epidemic within the population of
children with TB. HIV infection in
young adults has resulted in a large
number of HIV-infected infants, the
result of a lack of any large-scale pro-
gram aimed at preventing vertical
transmission. To combat the growing
problem with HIV-infected infants,
India’s National AIDS Control Orga-
nization is performing feasibility stud-
ies for implementing interventions to
prevent mother-to-child transmission
of HIV infection. Clinical trials with
nevirapine are currently being con-
ducted at five major public hospitals
in Mumbai. 
Multidrug-resistant TB frequently
develops in adult AIDS patients (7).
Accordingly, many pediatric AIDS
patients in Mumbai are also develop-
ing primary multidrug-resistant TB.
Since most families cannot afford anti-
retroviral therapy, HIV-infected chil-
dren in whom TB is diagnosed are
prescribed a four-drug TB treatment
(consisting of isoniazid, rifampicin,
pyrazinamide, and ethambutol) and
co-trimoxazole for Pneumocystis cari-
nii pneumonia prophylaxis. Although
deaths in these children are being
attributed to AIDS, we think that
many of these deaths are related to
multidrug-resistant TB. 
To combat the TB epidemic, the
Revised National Tuberculosis Con-
trol Program directly observed treat-
ment strategy has been implemented
as part of a public health program.
However, most patients receive treat-
ment from private physicians and thus
remain outside the purview of the
strategy. Private physicians seldom
refer their patients to centers offering
directly observed treatments because
of potential for loss of income (3). In
1991, Uplekar and Shepard (10)
reported that 100 private physicians in
the Dharavi slums in Mumbai pre-
scribed 80 different anti-TB regimens;
most were both inappropriate and
expensive. Since private physicians
have not yet been involved in the gov-Emerging Infectious Diseases  •  Vol. 8, No. 11, November 2002 1361
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ernment-run Revised National Tuber-
culosis Control Program, the situation
today remains the same. 
Although children are included in
the national control program, they do
not receive the benefit of directly
observed treatment strategy. The
Revised National Tuberculosis Con-
trol Program does not provide drugs in
syrup form or permit breaking of tab-
lets, making the administration of
accurate pediatric doses impossible.
Most children with TB are also spu-
tum-smear negative for acid-fast
bacilli. Doctors must rely on clinical
acumen when deciding whether or not
to start TB treatment. This lack of a
method for definitive diagnosis of TB
in children makes treatment centers
reluctant to enlist pediatric cases; as a
result, these children attend general
pediatric outpatient clinics every 28
days to obtain their TB medication.
Directly observed treatment strategy is
not followed in the general outpatient
clinics.  Hence, compliance with treat-
ment depends on the motivation and
perseverance of the parents. Fre-
quently, one or more of the drugs is
out of stock, and parents must use
their own small resources to purchase
the necessary medication. To avoid
long waits in the crowded general
pediatric outpatient clinics, some par-
ents intermittently purchase the anti-
TB drugs from local chemists, who
supply the drugs without a current pre-
scription. This practice leads to fre-
quent defaulting and inadequate
treatment. 
Since children in general have
paucibacillary TB, secondary multi-
drug-resistant TB is considered less
likely to develop in them, even when
the treatment is inadequate. However,
Karande et al. (11) describe a 12-year-
old boy in Mumbai with secondary
multidrug-resistant TB. He had
received multiple courses of inade-
quate treatment with various anti-TB
treatment regimens for 9 years. The
TB gradually progressed in severity
and was disseminated with the bacte-
rial load increasing sufficiently for
multidrug-resistant TB to develop. We
suggest that this case is not unusual
and that many children in Mumbai are
dying of multidrug-resistant TB
because directly observed treatment
strategy regimens are unavailable.
The multidrug-resistant TB crisis
on Mumbai’s children warrants imme-
diate attention and action. We suggest
that the directly observed treatment
strategy should be made child-friendly
with anti-TB drugs made available in
suitable pediatric formulations. Pri-
vate physicians require education and
involvement in the treatment strategy.
BACTEC (BD Diagnostic Systems,
Sparks, MD) culture and susceptibility
testing to detect multidrug-resistant
TB should be made available at
affordable rates. Transmission of HIV
to newborns would be reduced by uni-
versally implementing a prevention
program for mother-to-child transmis-
sion at subsidized rates. Immediate
action on these suggestions will lower
the incidence of both TB and multi-
drug-resistant TB and reduce the num-
ber of deaths from these diseases.
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Certificate of Knowledge 
in Travel Medicine 
Examination
The International Society of Travel
Medicine (ISTM) will offer its first
international Certificate of Knowledge
in Travel Medicine examination on May
7, 2003, before the opening of the 8th
ISTM Conference in New York City, on
May 7–11. Those passing the exam will
receive a Certificate in Travel Health.
The exam is open to all licensed travel
medicine practitioners, including physi-
cians, nurses, and pharmacists. 
To obtain more information on prep-
aration for taking the exam, registration,
and a Candidate Bulletin of Information,
please access the ISTM website at
www.istm.org. Applicants may also con-
tact Brenda Bagwell, ISTM Secretariat,
P.O. Box 871089, Stone Mountain, GA,
30087-0028. USA. Telephone: 1-770-
736-7060; fax: 1-770-736-6732; e-mail:
exam@istm.org 